Citadel Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Citadel Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.68M	Sell	127,800 -170,200	-57%	-$3.83M	﹤0.01%	5490
2025 Q4	$6.85M	Buy	298,000 +207,200	+228%	+$6.81M	﹤0.01%	3801
2025 Q3	$2.73M	Buy	90,800 +22,900	+34%	+$687K	﹤0.01%	5475
2025 Q2	$2.47M	Sell	67,900 -2,700	-4%	-$97.3K	﹤0.01%	5330
2025 Q1	$2.56M	Buy	70,600 +10,800	+18%	+$449K	﹤0.01%	5060
2024 Q4	$2.52M	Buy	59,800 +37,300	+166%	+$1.85M	﹤0.01%	5166
2024 Q3	$1.25M	Sell	22,500 -9,300	-29%	-$474K	﹤0.01%	6401
2024 Q2	$1.31M	Sell	31,800 -6,900	-18%	-$295K	﹤0.01%	6093
2024 Q1	$1.81M	Buy	38,700 +11,800	+44%	+$557K	﹤0.01%	5723
2023 Q4	$1.29M	Buy	26,900 +8,100	+43%	+$314K	﹤0.01%	6183
2023 Q3	$670K	Buy	18,800 +10,200	+119%	+$404K	﹤0.01%	7420
2023 Q2	$397K	Sell	8,600 -800	-9%	-$37.1K	﹤0.01%	8428
2023 Q1	$377K	Sell	9,400 -7,800	-45%	-$335K	﹤0.01%	8890
2022 Q4	$797K	Sell	17,200 -21,800	-56%	-$857K	﹤0.01%	7259
2022 Q3	$1.61M	Buy	39,000 +18,700	+92%	+$961K	﹤0.01%	6007
2022 Q2	$1.21M	Buy	20,300 +11,400	+128%	+$702K	﹤0.01%	6579
2022 Q1	$646K	Buy	8,900 +900	+11%	+$62.6K	﹤0.01%	8773
2021 Q4	$673K	Buy	8,000 +4,200	+111%	+$342K	﹤0.01%	8927
2021 Q3	$343K	Sell	3,800 -3,000	-44%	-$271K	﹤0.01%	10759
2021 Q2	$648K	Sell	6,800 -6,700	-50%	-$698K	﹤0.01%	9424
2021 Q1	$1.54M	Sell	13,500 -3,800	-22%	-$517K	﹤0.01%	7034
2020 Q4	$2.4M	Buy	17,300 +14,800	+592%	+$1.76M	﹤0.01%	4981
2020 Q3	$205K	Sell	2,500 -15,000	-86%	-$1.24M	﹤0.01%	8761
2020 Q2	$1.37M	Sell	17,500 -9,600	-35%	-$635K	﹤0.01%	5249
2020 Q1	$1.2M	Buy	27,100 +12,400	+84%	+$644K	﹤0.01%	4996
2019 Q4	$628K	Sell	14,700 -52,100	-78%	-$2.15M	﹤0.01%	6439
2019 Q3	$2.86M	Buy	66,800 +33,900	+103%	+$1.84M	﹤0.01%	3924
2019 Q2	$2.09M	Buy	32,900 +22,500	+216%	+$1.43M	﹤0.01%	4441
2019 Q1	$721K	Buy	10,400 +2,600	+33%	+$149K	﹤0.01%	6162
2018 Q4	$339K	Sell	7,800 -800	-9%	-$43.7K	﹤0.01%	7051
2018 Q3	$657K	Buy	8,600 +4,400	+105%	+$358K	﹤0.01%	6259
2018 Q2	$323K	Sell	4,200 -1,500	-26%	-$96.9K	﹤0.01%	7089
2018 Q1	$291K	Buy	+5,700	New	+$287K	﹤0.01%	6795
2017 Q3	–	Sell	-6,400	Closed	-$398K	–	7937
2017 Q2	$398K	Buy	+6,400	New	+$386K	﹤0.01%	5461
2017 Q1	–	Sell	-5,000	Closed	-$352K	–	7923
2016 Q4	$352K	Sell	5,000 -6,800	-58%	-$482K	﹤0.01%	5444
2016 Q3	$837K	Buy	11,800 +3,200	+37%	+$204K	﹤0.01%	4064
2016 Q2	$421K	Sell	8,600 -300	-3%	-$19.4K	﹤0.01%	4732
2016 Q1	$563K	Buy	8,900 +7,400	+493%	+$484K	﹤0.01%	4244
2015 Q4	$168K	Sell	1,500 -5,700	-79%	-$570K	﹤0.01%	6030
2015 Q3	$693K	Buy	7,200 +6,100	+555%	+$698K	﹤0.01%	4317
2015 Q2	$113K	Buy	+1,100	New	+$85.4K	﹤0.01%	6965

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Citadel Advisors's RARE Position: Q1 2026 in Review

Citadel Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 9.1% in Q1 2026, selling an estimated $4.74M and leaving 2,115,491 shares worth $44.3M. The position accounts for 0.01% of the portfolio, ranked #1472.

Citadel Advisors first reported a position in RARE in Q1 2014 and has held it in 48 quarters since. The position peaked at $177M in Q2 2021. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Citadel Advisors held 2,115,491 shares of Ultragenyx Pharmaceutical worth $44.3M as of Q1 2026.
Citadel Advisors sold 210,634 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.74M.
Ultragenyx Pharmaceutical made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1472 holding.
Citadel Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 48 quarters since.
Citadel Advisors's Ultragenyx Pharmaceutical position peaked at $177M in Q2 2021.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.